These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34789416)

  • 1. Cardiovascular autonomic dysfunction is associated with executive dysfunction and poorer quality of life in progressive supranuclear palsy-Richardson's syndrome.
    Liu P; Chen Y; Wang B; Wu S; Zeng L; Cen Z; Yang D; Wang H; Chen X; Wang L; Ouyang Z; Luo W
    J Clin Neurosci; 2022 Feb; 96():147-153. PubMed ID: 34789416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of autonomic dysfunction in patients with Parkinson's Disease, progressive supranuclear palsy, and multiple system atrophy.
    Malkiewicz JJ; Siuda J
    Neurol Neurochir Pol; 2024; 58(2):193-202. PubMed ID: 38148738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Executive dysfunction, behavioral changes and quality of life in Chinese patients with progressive supranuclear palsy.
    Ou R; Liu H; Hou Y; Wei Q; Cao B; Zhao B; Shang H
    J Neurol Sci; 2017 Sep; 380():182-186. PubMed ID: 28870563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes.
    Schmidt C; Berg D; ; Prieur S; Junghanns S; Schweitzer K; Globas C; Schöls L; Reichmann H; Ziemssen T
    Mov Disord; 2009 Oct; 24(14):2136-42. PubMed ID: 19768815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor, cognitive and behavioral differences in MDS PSP phenotypes.
    Picillo M; Cuoco S; Tepedino MF; Cappiello A; Volpe G; Erro R; Santangelo G; Pellecchia MT; Barone P;
    J Neurol; 2019 Jul; 266(7):1727-1735. PubMed ID: 30989369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease.
    Zanigni S; Calandra-Buonaura G; Manners DN; Testa C; Gibertoni D; Evangelisti S; Sambati L; Guarino M; De Massis P; Gramegna LL; Bianchini C; Rucci P; Cortelli P; Lodi R; Tonon C
    Neuroimage Clin; 2016; 11():736-742. PubMed ID: 27330973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding fatigue in progressive supranuclear palsy.
    Ahn JH; Song J; Lee DY; Youn J; Cho JW
    Sci Rep; 2021 Aug; 11(1):16926. PubMed ID: 34413435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorodeoxyglucose positron emission tomography in Richardson’s syndrome and progressive supranuclear palsy-parkinsonism.
    Srulijes K; Reimold M; Liscic RM; Bauer S; Dietzel E; Liepelt-Scarfone I; Berg D; Maetzler W
    Mov Disord; 2012 Jan; 27(1):151-5. PubMed ID: 22359740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acoustical analysis of speech in progressive supranuclear palsy.
    Skodda S; Visser W; Schlegel U
    J Voice; 2011 Nov; 25(6):725-31. PubMed ID: 20457507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease.
    Pellicano C; Assogna F; Cellupica N; Piras F; Pierantozzi M; Stefani A; Cerroni R; Mercuri B; Caltagirone C; Pontieri FE; Spalletta G
    Parkinsonism Relat Disord; 2017 Dec; 45():50-56. PubMed ID: 29037499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDQ-8: A Simplified and Effective Tool Measuring Life Quality in Progressive Supranuclear Palsy.
    Li XY; Chen MJ; Liang XN; Yao RX; Shen B; Wu B; Li G; Sun YM; Wu JJ; Liu FT; Yang YJ; Wang J;
    J Parkinsons Dis; 2023; 13(1):83-91. PubMed ID: 36591660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease.
    Fiorenzato E; Antonini A; Camparini V; Weis L; Semenza C; Biundo R
    J Neural Transm (Vienna); 2019 Nov; 126(11):1437-1445. PubMed ID: 31432258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism.
    Assogna F; Pellicano C; Cravello L; Savini C; Macchiusi L; Pierantozzi M; Stefani A; Mercuri B; Caltagirone C; Pontieri FE; Spalletta G
    Brain Behav; 2019 Dec; 9(12):e01448. PubMed ID: 31743601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal cord stimulation therapy for gait dysfunction in progressive supranuclear palsy patients.
    Samotus O; Parrent A; Jog M
    J Neurol; 2021 Mar; 268(3):989-996. PubMed ID: 33011852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of Frontal Assessment Battery in detection of neuropsychological dysfunction in Richardson variant of progressive supranuclear palsy.
    Sitek EJ; Konkel A; Dąbrowska M; Sławek J
    Neurol Neurochir Pol; 2015; 49(1):36-40. PubMed ID: 25666771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the relationship between freezing of gait and other progressive supranuclear palsy features.
    Rezvanian S; Litvan I; Standaert D; Jankovic J; Reich SG; Hall D; Shprecher DR; Bordelon Y; Dubinsky R; Kluger B
    Parkinsonism Relat Disord; 2020 Sep; 78():56-60. PubMed ID: 32731191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of Blood Pressure Variability Indices Derived From 24-Hour Ambulatory Blood Pressure Monitoring in Detecting Autonomic Failure.
    Lodhi HA; Peri-Okonny PA; Schesing K; Phelps K; Ngo C; Evans H; Arbique D; Price AL; Vernino S; Phillips L; Mitchell JH; Smith SA; Yano Y; Das SR; Wang T; Vongpatanasin W
    J Am Heart Assoc; 2019 Apr; 8(7):e010161. PubMed ID: 30905258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, cognitive, and morphometric profiles of progressive supranuclear palsy phenotypes.
    Campagnolo M; Weis L; Fogliano C; Cianci V; Garon M; Fiorenzato E; Carecchio M; Ferreri F; Bisiacchi P; Antonini A; Biundo R
    J Neural Transm (Vienna); 2023 Feb; 130(2):97-109. PubMed ID: 36701008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autonomic dysfunction in patients with progressive supranuclear palsy.
    Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Reichmann H; Berg D; Ziemssen T
    Mov Disord; 2008 Oct; 23(14):2083-9. PubMed ID: 18792126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which ante mortem clinical features predict progressive supranuclear palsy pathology?
    Respondek G; Kurz C; Arzberger T; Compta Y; Englund E; Ferguson LW; Gelpi E; Giese A; Irwin DJ; Meissner WG; Nilsson C; Pantelyat A; Rajput A; van Swieten JC; Troakes C; Josephs KA; Lang AE; Mollenhauer B; Müller U; Whitwell JL; Antonini A; Bhatia KP; Bordelon Y; Corvol JC; Colosimo C; Dodel R; Grossman M; Kassubek J; Krismer F; Levin J; Lorenzl S; Morris H; Nestor P; Oertel WH; Rabinovici GD; Rowe JB; van Eimeren T; Wenning GK; Boxer A; Golbe LI; Litvan I; Stamelou M; Höglinger GU;
    Mov Disord; 2017 Jul; 32(7):995-1005. PubMed ID: 28500752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.